Copyright Reports & Markets. All rights reserved.

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Amyotrophic Lateral Sclerosis (ALS) Treatment by Type
    • 1.3.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Type in 2025
    • 1.3.3 Riluzole
    • 1.3.4 Edaravone (Radicava)
    • 1.3.5 Other
  • 1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
    • 1.4.1 Overview: Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Drugs Store
    • 1.4.4 Other
  • 1.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size & Forecast
  • 1.6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast by Region
    • 1.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region, (2021-2032)
    • 1.6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
    • 1.6.6 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Mitsubishi Tanabe Pharma
    • 2.1.1 Mitsubishi Tanabe Pharma Details
    • 2.1.2 Mitsubishi Tanabe Pharma Major Business
    • 2.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Mitsubishi Tanabe Pharma Recent Developments and Future Plans
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments and Future Plans
  • 2.3 Mylan Pharma
    • 2.3.1 Mylan Pharma Details
    • 2.3.2 Mylan Pharma Major Business
    • 2.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Mylan Pharma Recent Developments and Future Plans
  • 2.4 Apotex
    • 2.4.1 Apotex Details
    • 2.4.2 Apotex Major Business
    • 2.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Apotex Recent Developments and Future Plans
  • 2.5 Glemark Generics
    • 2.5.1 Glemark Generics Details
    • 2.5.2 Glemark Generics Major Business
    • 2.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Glemark Generics Recent Developments and Future Plans
  • 2.6 Covis Pharma
    • 2.6.1 Covis Pharma Details
    • 2.6.2 Covis Pharma Major Business
    • 2.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Covis Pharma Recent Developments and Future Plans
  • 2.7 Sun Pharma
    • 2.7.1 Sun Pharma Details
    • 2.7.2 Sun Pharma Major Business
    • 2.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sun Pharma Recent Developments and Future Plans
  • 2.8 Lunan Pharma
    • 2.8.1 Lunan Pharma Details
    • 2.8.2 Lunan Pharma Major Business
    • 2.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product and Solutions
    • 2.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Lunan Pharma Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Revenue
    • 3.2.2 Top 3 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
    • 3.2.3 Top 6 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share in 2025
  • 3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Overall Company Footprint Analysis
    • 3.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Region Footprint
    • 3.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Type Footprint
    • 3.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
  • 6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2032)
  • 6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
    • 6.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
    • 6.3.2 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
  • 7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
  • 7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
    • 7.3.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 7.3.3 France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region
    • 8.3.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Region (2021-2032)
    • 8.3.2 China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 8.3.5 India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
  • 9.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
  • 9.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
    • 9.3.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country
    • 10.3.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
  • 11.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
  • 11.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Chain
  • 12.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Upstream Analysis
  • 12.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Midstream Analysis
  • 12.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market size was valued at US$ 387 million in 2025 and is forecast to a readjusted size of US$ 655 million by 2032 with a CAGR of 7.9% during review period.
    Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
    The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person"s parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person"s signs and symptoms, with testing done to rule out other potential causes.
    GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
    North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
    In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.
    This report is a detailed and comprehensive analysis for global Amyotrophic Lateral Sclerosis (ALS) Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Amyotrophic Lateral Sclerosis (ALS) Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Amyotrophic Lateral Sclerosis (ALS) Treatment market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Amyotrophic Lateral Sclerosis (ALS) Treatment
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Amyotrophic Lateral Sclerosis (ALS) Treatment market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Riluzole
    Edaravone (Radicava)
    Other
    Market segment by Application
    Hospital
    Drugs Store
    Other
    Market segment by players, this report covers
    Mitsubishi Tanabe Pharma
    Sanofi
    Mylan Pharma
    Apotex
    Glemark Generics
    Covis Pharma
    Sun Pharma
    Lunan Pharma
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Amyotrophic Lateral Sclerosis (ALS) Treatment, with revenue, gross margin, and global market share of Amyotrophic Lateral Sclerosis (ALS) Treatment from 2021 to 2026.
    Chapter 3, the Amyotrophic Lateral Sclerosis (ALS) Treatment competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Amyotrophic Lateral Sclerosis (ALS) Treatment market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Amyotrophic Lateral Sclerosis (ALS) Treatment.
    Chapter 13, to describe Amyotrophic Lateral Sclerosis (ALS) Treatment research findings and conclusion.

    Buy now